Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

At the STAT summit, executives discuss their challenges, and hopeful signals, about breaking into markets on obesity and ...

An investor is suing Amgen Inc.'s leaders over the company’s $10.7 billion fight with the IRS, which has said the ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

nVerses Capital LLC grew its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 800.0% in the 3rd quarter, according to the ...

DBS analyst Nico Chen has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

No matter what happens, investing in companies that will get through bear markets and perform well over the long run is ...

Dividend stocks can be a great way to supplement your portfolio growth from share price gains and inject more cash into your ...

The fact that multiple Amgen Inc. (NASDAQ:AMGN) insiders offloaded a considerable amount of shares over the past year could ...

Amgen Inc.'s stock took a hit Monday after the biotechnology giant lost a bull, amid concerns that prices already reflect investor optimism over the obesity drug candidate, leaving more downside ...